VA Continues to Prohibit Doctors from Prescribing Cannabis to Veteran Patients -
The U.S. Department of Veterans Affairs (VA) issued a directive, consistent with a previous directive released in 2017, which prevents...more
Congressional Activity—New Hearing and Bipartisan Bill on Hemp -
On July 20, the Hemp Access and Consumer Safety Act was reintroduced in Congress with bipartisan support from co-sponsors Sen. Ron Wyden, D-Ore., Sen. Rand...more
DEA Announces New Guidance for Synthetic Cannabinoids -
On June 9, the U.S. Drug Enforcement Administration (DEA) issued a letter in response to a request for information about the scheduling status of minor and synthetic...more
Cannabis: In Focus -
- DEA Classifies Two Lab-Derived Cannabinoids as Schedule I
- Washington Federal Judge Dismisses Suit Challenging Residency Requirements...more
3/7/2023
/ Appeals ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Commercial Litigation ,
DEA ,
Dismissals ,
Food and Drug Administration (FDA) ,
Investors ,
Licenses ,
Marijuana ,
Non-Residents ,
Schedule I Drugs ,
THC ,
Washington
The U.S. Food and Drug Administration (FDA) recently released new guidance on sourcing and product quality to companies conducting clinical research related to the development of human drugs involving cannabis or...more
2/6/2023
/ Cannabis Products ,
Clinical Trials ,
Controlled Substances Act ,
DEA ,
Farm Bill ,
Food and Drug Administration (FDA) ,
Hemp ,
Marijuana ,
New Guidance ,
NIDA ,
Regulatory Standards ,
Research and Development ,
THC